Resource Summary Report

Generated by NIF on Sep 18, 2026

OVCAR-8

RRID:CVCL_1629
Type: Cell Line

Proper Citation

RRID:CVCL_1629

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1629

Proper Citation: RRID:CVCL_1629

Description: Cell line OVCAR-8 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: PMID:1348364, PMID:2041050, PMID:2307530, PMID:3335022, PMID:7718330, PMID:9041185, PMID:9331090, PMID:10700174, PMID:12417041, PMID:12960427, PMID:15748285, PMID:17088437, PMID:19372543, PMID:20164919, PMID:20204287, PMID:21912889, PMID:22068913, PMID:22336246, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22585861, PMID:22628656, PMID:22710073, PMID:23415752, PMID:23839242, PMID:23856246, PMID:23933261, PMID:24023729, PMID:24279929, PMID:24670534, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27235858, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28196595, PMID:28273451, PMID:30485824, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31733513, PMID:31978347, PMID:35839778, PMID:38861359

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVCAR-8

Synonyms: OVCAR 8, NIH:OVCAR-8, OVCAR8, Ovcar8, OVCAR.8, OVCA8

Cross References: BTO:BTO_0003054, EFO:EFO_0005444, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:392, BioSample:SAMN03472794, BioSample:SAMN10988023, cancercelllines:CVCL_1629, Cell_Model_Passport:SIDM00090, ChEMBL-Cells:CHEMBL3307975, ChEMBL-Targets:CHEMBL612555, CLS:305383, Cosmic:688106, Cosmic:875862, Cosmic:905991, Cosmic:974298, Cosmic:1044242, Cosmic:1092626, Cosmic:1093555, Cosmic:1305315, Cosmic:1312357, Cosmic:1436036, Cosmic:1523764, Cosmic:1526923, Cosmic:1998468, Cosmic:2186582, Cosmic-CLP:905991, DepMap:ACH-000696, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905991, GEO:GSM2117, GEO:GSM50222, GEO:GSM50286, GEO:GSM185143, GEO:GSM185144, GEO:GSM322534, GEO:GSM322535, GEO:GSM322536, GEO:GSM459646, GEO:GSM459647, GEO:GSM711710, GEO:GSM743477, GEO:GSM743495, GEO:GSM750819, GEO:GSM750831, GEO:GSM784574, GEO:GSM799366, GEO:GSM799429, GEO:GSM844672, GEO:GSM844673, GEO:GSM847109, GEO:GSM851937, GEO:GSM887485, GEO:GSM888566, GEO:GSM1153438, GEO:GSM1181299, GEO:GSM1181339, GEO:GSM1340588, GEO:GSM1341132, GEO:GSM1374803, GEO:GSM1670320, GEO:GSM2124679, GEO:GSM2474994, GEO:GSM2748150, GEO:GSM2748151, GEO:GSM2748152, GEO:GSM2748153, GEO:GSM2748154, GEO:GSM2748155, GEO:GSM3161724, GEO:GSM3161725, IARC_TP53:18079, IARC_TP53:21121, LiGeA:CCLE_464, NCI-DTP:OVCAR-8, PharmacoDB:OVCAR8_1220_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1629, PubChem_Cell_line:CVCL_1629, SKY/M-FISH/CGH:1437, Wikidata:Q54937014

ID: CVCL_1629

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260913T005704+0000

Ratings and Alerts

No rating or validation information has been found for OVCAR-8.

No alerts have been found for OVCAR-8.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 389 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. Immunity, 59(6), 1743.

Sheedy AM, et al. (2026) A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer. Device, 4(3).

Qiao M, et al. (2026) ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(16), e13310.

Scholler J, et al. (2026) Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer. Frontiers in immunology, 17, 1805950.

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Zhang Y, et al. (2026) Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. eLife, 13.

Li Y, et al. (2026) Disruption of the SNRPF-DDX24-E2F4 Feedback Loop Uncouples Splicing and Transcriptional Regulation to Suppress Ovarian Cancer Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e23374.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell reports. Medicine, 7(4), 102694.

Saleh A, et al. (2026) CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3. Molecular oncology.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and ?3?1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. Cancer research, 86(1), 99.

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. British journal of cancer, 134(12), 1830.

Kang Z, et al. (2026) LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling. Genome biology, 27(1).

Lujano-Olazaba O, et al. (2026) RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. Cell reports, 45(7), 117650.

Sahm BDB, et al. (2026) Anticancer Potential of Piericidin A1 and Derivatives Isolated From Streptomyces sp. Associated With Palythoa variabilis From Brazilian Reefs. Chemistry & biodiversity, 23(4), e03815.

Keovilay JA, et al. (2026) Isoquercetin and Zafirlukast Cooperatively Suppress Tumor Growth and Thromboinflammatory Signaling in a Xenograft Model of Ovarian Cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(1), e71361.

Meng Y, et al. (2026) IPO9 Promotes Ovarian Cancer Progression by Suppressing HMOX1-Dependent Ferroptosis. Human mutation, 2026, 8545131.

Rahman I, et al. (2026) Self-assembled verteporfin nanoparticles decrease drug efflux by P-glycoprotein without light activation in drug-resistant cancer cells. Bioengineering & translational medicine, 11(4), e70136.

Ma J, et al. (2025) Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. Cellular oncology (Dordrecht, Netherlands), 48(6), 1837.

Zhang S, et al. (2025) Vertical inhibition of p110?/AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells. Molecular oncology, 19(4), 1132.